The use of cetuximab was approved for the first time in 2004 for the treatment of colorectal cancer, which has high response rates to this drug (about 47% of the patients)[8], although there is no concordance in the literature about the role of EGFR expression as a biomarker for response to this targeted therapy[32-34]. The gene discussed is EGFR; the disease is colorectal cancer.